Surprising Wall Street, Reata unveils positive pivotal data on Friedreich’s ataxia drug
Days after Reata Pharmaceuticals untethered itself from its partnership with AbbVie, the Texas-based drug developer is off to the regulators with positive pivotal data on omaveloxolone, an experimental drug analysts were not particularly banking on.
Omaveloxolone, like Reata’s other lead drug — bardoxolone — is a small molecule engineered to bind to a gene called Keap1 to enhance the activity of the protein Nrf2 in order to defuse inflammation. The drug was being tested in a two-part mid-stage trial in patients with Friedreich’s ataxia (FA), an inherited degenerative neuromuscular disorder for which there are no approved therapies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.